Intelligent Delivery Systems in Tumor Metabolism Regulation: Exploring the Path Ahead

Li, Xuwen; Sun, Tao; Jiang, Chen

doi:10.1002/adma.202309582

Cited by 7 publications

(1 citation statement)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug delivery system (DDS) is a technical system that can control the distribution of drugs in the body in a spatiotemporal and dosing manner. DDS can improve the targeting and selectivity of drugs, enhance the stability and bioavailability of drugs, achieve synergistic enhancement and multidimensional treatment of drugs, thereby improving the effect and safety of tumor treatment ( Vargason et al, 2021 ; Yi et al, 2022 ; Li et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Magnetic-driven hydrogel microrobots for promoting osteosarcoma chemo-therapy with synthetic lethality strategy

Tao,

Li,

Yang

et al. 2024

Front. Chem.

View full text Add to dashboard Cite

The advancements in the field of micro-robots for drug delivery systems have garnered considerable attention. In contrast to traditional drug delivery systems, which are dependent on blood circulation to reach their target, these engineered micro/nano robots possess the unique ability to navigate autonomously, thereby enabling the delivery of drugs to otherwise inaccessible regions. Precise drug delivery systems can improve the effectiveness and safety of synthetic lethality strategies, which are used for targeted therapy of solid tumors. MYC-overexpressing tumors show sensitivity to CDK1 inhibition. This study delves into the potential of Ro-3306 loaded magnetic-driven hydrogel micro-robots in the treatment of MYC-dependent osteosarcoma. Ro-3306, a specific inhibitor of CDK1, has been demonstrated to suppress tumor growth across various types of cancer. We have designed and fabricated this micro-robot, capable of delivering Ro-3306 precisely to tumor cells under the influence of a magnetic field, and evaluated its chemosensitizing effects, thereby augmenting the therapeutic efficacy and introducing a novel possibility for osteosarcoma treatment. The clinical translation of this method necessitates further investigation and validation. In summary, the Ro-3306-loaded magnetic-driven hydrogel micro-robots present a novel strategy for enhancing the chemosensitivity of MYC-dependent osteosarcoma, paving the way for new possibilities in future clinical applications.

show abstract

Section: Introductionmentioning

confidence: 99%

Magnetic-driven hydrogel microrobots for promoting osteosarcoma chemo-therapy with synthetic lethality strategy

Tao,

Li,

Yang

et al. 2024

Front. Chem.

View full text Add to dashboard Cite

show abstract

High‐Lactate‐Metabolizing Photosynthetic Bacteria Reprogram Tumor Immune Microenvironment

Ma,

Hu,

Liu

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

The elevated levels of lactate in tumor tissue play a pivotal role in fostering an immunosuppressive microenvironment. Therefore, efficiently reducing lactate levels to reprogram tumor immune microenvironment (TIM) is considered a crucial step for boosted immunotherapy. Here, a high‐lactate‐metabolizing photosynthetic bacteria (LAB‐1) is selectively screened for TIM reprogramming, which then improves the efficacy of tumor immunotherapy. The culture medium for LAB‐1 screening is initially developed through an orthogonal experiment, simulating the tumor microenvironment (TME) and utilizing lactate as the sole organic carbon source. As demonstrated in a murine 4T1 model, LAB‐1 colonizes the TME selectively, resulting in a significant reduction in lactate levels and a subsequent increase in pH values within the tumor tissue. Furthermore, single‐cell RNA sequencing analysis reveals that LAB‐1 effectively reprograms the TIM, thereby enhancing the effectiveness of antitumor immune therapy. This approach of utilizing lactate‐consuming bacteria represents a potent tool for augmenting tumor immunotherapy efficiency.

show abstract

A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD‐L1 Therapy

Xu,

Wu,

Zheng

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Combination therapy has become a promising strategy for promoting the outcomes of anti‐programmed death ligand‐1 (αPD‐L1) therapy in lung cancer. Among all, emerging strategies targeting cancer metabolism have shown great potency in treating cancers with immunotherapy. Here, alteration in glucose and copper metabolisms is found to synergistically regulate PD‐L1 expression in lung cancer cells. Thus, an intelligent biomimetic nano‐delivery system is synthesized by camouflaging lung cancer cell membranes onto glucose oxidase‐loaded Cu‐LDHs (CMGCL) for cancer metabolism targeted interference. Such novel nanomedicine is able to induce lung cancer cell cuproptosis and PD‐L1 upregulation significantly via self‐amplified cascade reactions. Meanwhile, with a decent cancer cell membrane coating, CMGCL exhibited great biosafety, tumor‐targeted efficiency and anti‐tumor effects in LLC lung tumor‐bearing mice models. Additionally, a combination of CMGCL can sensitize the therapeutic effects of αPD‐L1, substantially promoting tumor inhibition in both subcutaneous and lung metastasis LLC‐bearing mice models. Overall, these findings highlight the potential connections between glucose metabolism and cell cuproptosis, offering a promising approach for treating lung cancer by integrating starvation, cuproptosis, and immunotherapy.

show abstract

Intelligent Delivery Systems in Tumor Metabolism Regulation: Exploring the Path Ahead

Cited by 7 publications

References 110 publications

Magnetic-driven hydrogel microrobots for promoting osteosarcoma chemo-therapy with synthetic lethality strategy

Magnetic-driven hydrogel microrobots for promoting osteosarcoma chemo-therapy with synthetic lethality strategy

High‐Lactate‐Metabolizing Photosynthetic Bacteria Reprogram Tumor Immune Microenvironment

A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD‐L1 Therapy

Contact Info

Product

Resources

About